United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2.5mmol) tablets (special order - magnesium aspartate hydrochloride - oral tablet - 60.8mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 5mmol) oral powder sachets (special order - magnesium aspartate hydrochloride - powder - 121.5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 23.705 mg (equivalent: vardenafil, qty 20 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 11.852 mg (equivalent: vardenafil, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 5.926 mg (equivalent: vardenafil, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2.5mmol) tablets (imported (germany) - magnesium aspartate hydrochloride - oral tablet - 60.8mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 5mmol) oral powder 5g sachets (imported (germany) - magnesium aspartate hydrochloride - powder - 121.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 7.5mmol) effervescent tablets (imported (germany) - magnesium aspartate hydrochloride - effervescent tablet - 182.3mg

United States - English - NLM (National Library of Medicine)

fresenius kabi norge as - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 80 mg in 1 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.  when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant.  however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .